Cargando…
Should a Multigene Signature be Used in all Luminal Early Breast Cancers
Background: Multigene signatures refine the risk of recurrence and guide adjuvant chemotherapy decision in luminal breast cancers. The decision to perform the assay is highly variable among oncologists. In order to guide the appropriate clinical group in whom to perform a genomic signature, our stud...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558017/ https://www.ncbi.nlm.nih.gov/pubmed/31214499 http://dx.doi.org/10.3389/fonc.2019.00454 |